

preparation of selected steroid esters was contracted by WHO and the resulting compounds screened by the Contraceptive Development Branch (CDB) of the National Institute for Child Health and Human Development at its Biological Testing Facility. Chemically, testosterone bucyclate is Testosterone 17 $\beta$ -(*trans*-4-*n*-butyl) cyclohexyl carboxylate. This ester of the natural hormone, testosterone, exhibits prolonged activity when administered intramuscularly as an aqueous crystalline suspension in all species studied, including man. The drug was evaluated, including pharmacokinetics and metabolic studies in both rodents and primates, by CDB. WHO supported studies in primates as well as the first clinical studies in hypogonadal and normal men. The patent is jointly held by NIH and WHO. NIH and WHO intend to continue joint development of testosterone bucyclate.

Although each patentee may proceed with granting a non-exclusive license independently, joint licensing is envisaged. Licensing will include use of testosterone bucyclate as a hormonal method of male contraception, use for androgen replacement in other methods of male contraception, which usually compromise the endocrine as well as the gametogenic function of the testis and use as a therapeutic androgen for patients with androgen deficiency syndromes. A "Notice of Claimed Investigational Exemption For A New Drug" (IND) is currently being prepared.

The National Institute of Child Health and Human Development and the World Health Organization seek partners for the further development and commercialization of testosterone bucyclate.

The role of the National Institute of Child Health and Human Development and the World Health Organization is expected to be as follows:

1. Provide the commercial partner with all biological data on testosterone bucyclate covered by the agreement.
2. Provide samples of the drug and clinical dosage forms.
3. Provide chemical data on testosterone bucyclate, including routes of synthesis, analytical methods employed, purity, stability and formulation.
4. Provide reports of all safety studies of the drug.
5. Continue studies on the pharmacokinetics and biological activity of testosterone bucyclate and formulations thereof.
6. Conduct appropriate studies to optimize formulations of testosterone bucyclate.
7. Prepare the IND.

8. Participate in meetings with the Food and Drug Administration for establishment of the protocols for Phase I, II and III clinical investigations and provide liaison with the FDA.

The role of the commercial partner is expected to be as follows;

1. Obtain a commercialization license from NIH and the WHO.
2. Participate in the development of the IND.
3. Assume responsibility for regulatory affairs.
4. Assume responsibility for preparation and formulation of the drug for pre-Phase III safety studies and Phase III clinical trials.
5. Undertake such additional safety studies as may be required for Phase III clinical trials and for NDA submission.
6. Undertake an orderly sequence of clinical investigations of testosterone bucyclate as a hormonal method of male contraception and for androgen replacement in other methods of male contraception.
7. Assume responsibility for preparation and filing of the NDA.
8. Assume responsibility for commercial manufacture and distribution of the final products.
9. Ensure availability of the final products to the public sector of developing countries in sufficient quantities, at a preferential price, in accordance with WHO's public sector objectives.

Selection criteria for choosing commercial partners will furthermore include, but will not be limited to the following:

1. The proposal must contain a clear statement of capabilities and experience with respect to the tasks to be undertaken. This would include experience in drug development, regulatory affairs and marketing.
2. The proposal must contain a clear and concise outline of the work to be undertaken, a schedule of significant events, an outline of objectives to be accomplished with individual and overall times frames, and details of experimental procedures and techniques to be employed.
3. The proposal must contain the level of financial support which will be supplied for the development of testosterone bucyclate.
4. Agreement to be bound by DHHS and WHO rules and regulations regarding patent rights, the ethical treatment of animals, the involvement of human subjects in clinical investigations and the conduct of randomized clinical trials.
5. Agreement with provisions for equitable distribution of patent rights to any inventions developed under the CRADA and license agreements.

**EFFECTIVE DATE:** In view of the high priority for developing and commercializing testosterone bucyclate, all proposals must be received no later than September 5, 1995 for priority consideration.

**ADDRESSES:** CRADA proposals and questions should be addressed to Dr. Gordon Guroff, Deputy Scientific Director, National Institutes of Child Health and Human Development, Building 49, Room 5A64, Bethesda, Maryland 20892 (Telephone: 301/496-4751); with a copy to Director, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, 20, Avenue Appia, CH-1211 Geneva 27, Switzerland. Responders interested in submitting a CRADA should simultaneously submit a license application concerning the above-mentioned patent rights to NIH and WHO for commercialization of products arising from the CRADA.

Requests for copies of the U.S. patent, license application forms, or questions about the licensing opportunity should be addressed to Ms. Carol Lavrich, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (Telephone: 301/496-7735 ext. 287), with a copy to Office of the Legal Counsel, World Health Organization, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland (Telephone: 00-41-22 7912685). Completed license applications should be submitted to the same addresses.

Pertinent information not yet publicly described can be obtained under a Confidential Disclosure Agreement with the appropriate agency.

Dated: May 24, 1995.

**Barbara M. McGarey,**  
Deputy Director, Office of Technology Transfer.

[FR Doc. 95-13711 Filed 6-5-95; 8:45 am]

BILLING CODE 4140-01-P

#### **National Institute of Nursing Research; Meetings of the National Advisory Council for Nursing Research and its Subcommittees**

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Advisory Council for Nursing Research, National Institute of Nursing Research, National Institutes of Health; and its Subcommittees, June 16 and June 20-21, 1995.

The meetings will be open to the public as indicated below. Attendance will be limited to space available.

The meetings will be closed to the public as indicated below in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, for the review, discussion and evaluation of individual grant applications. These applications and discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Summaries of meetings, rosters of committee members, and other information may be obtained from the Executive Secretary listed below. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the Executive Secretary in advance of the meeting.

*Name of Committee:* National Advisory Council for Nursing Research.

*Date of Meeting:* June 20-21, 1995.

*Place:* National Institutes of Health, Building 45 (Natcher), Conference Room D, Bethesda, MD.

*Open:* June 20—1:30 p.m. to 5 p.m.

*Agenda:* NINR Director's Report, Report on Research Roundtable Meetings and Research Training, NACRN Subcommittee Issues, Report on Reinventing Government.

*Closed:* June 21—8:30 a.m. to adjournment.

*Name of Committee:* Planning Subcommittee.

*Date of Meeting:* June 16, 1995 (Telephone Conference).

*Place:* National Institutes of Health, Building 31, Conference Room 5B03, Bethesda, MD.

*Open:* 1 p.m. to 2:30 p.m.

*Agenda:* Discuss long-term and strategic planning and policy issues.

*Executive Secretary:* Dr. Ernest Marquez, NINR, NIH, Building 45, Room 3AN.12, Bethesda, MD 20892 (301) 594-5965.

*Name of Committee:* Nursing Research Subcommittee.

*Date of Meeting:* June 16, 1995 (Telephone Conference).

*Place:* National Institutes of Health, Building 31, Conference Room 5B03, Bethesda, MD.

*Closed:* 10:30 a.m. to 12:30 p.m.

(Catalog of Federal Domestic Assistance Program No. 93.361, Nursing Research, National Institutes of Health.)

Dated: May 30, 1995.

**Susan K. Feldman,**

*Committee Management Officer, NIH.*

[FR Doc. 95-13719 Filed 6-5-95; 8:45 am]

BILLING CODE 4140-01-M

### National Institute of Dental Research; Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

*Committee Name:* National Institute of Dental Research Special Review Committee Meeting.

*Dates:* June 15-16, 1995.

*Time:* 8:00 a.m.

*Place:* Hyatt Regency Hotel, Bethesda, One Bethesda Metro Center, Bethesda, Maryland 20814.

*Contact Person:* Dr. William Gartland, Scientific Review Administrator, 4500 Center Drive, Natcher Building, Room 4AN-38E, Bethesda, MD 20892, (301) 594-2372.

*Purpose/Agenda:* To evaluate and review grant applications and/or contract proposals.

The meetings will be closed in accordance with the provision set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the extramural research review cycle.

(Catalog of Federal Domestic Assistance Program No. 93.121, Oral Diseases and Disorders Research.)

Dated: May 30, 1995.

**Susan K. Feldman,**

*Committee Management Officer, NIH.*

[FR Doc. 95-13717 Filed 6-5-95; 8:45 am]

BILLING CODE 4140-01-M

### National Institute on Deafness and Other Communication Disorders; Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

*Name of Committee:* National Institute on Deafness and Other Communication Disorders Special Emphasis Panel.

*Date:* June 16, 1995.

*Time:* 1 p.m. to 3 p.m.

*Place:* 6120 Executive Boulevard, Room 400C, Rockville, MD 20852.

*Contact Person:* Marilyn Semmes, Ph.D., Acting Chief, Scientific Review Branch, DEA, NIDCD, NIH, EPS Room 400C, 6120 Executive Boulevard, MSC 7180, Bethesda, MD 20892-7180, 301/496-8683.

*Purpose/Agenda:* To review and evaluate a contract proposal.

The meeting, which will be conducted as a telephone conference call, will be closed in

accordance the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review cycle.

(Catalog of Federal Domestic Assistance Program No. 93.173 Biological Research Related to Deafness and Communication Disorders.)

Dated: May 30, 1995.

**Susan K. Feldman,**

*Committee Management Officer, NIH.*

[FR Doc. 95-13718 Filed 6-5-95; 8:45 am]

BILLING CODE 4140-01-M

### Division of Research Grants; Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Behavioral and Neurosciences.

*Date:* June 23, 1995.

*Time:* 8:30 a.m.

*Place:* Jefferson Hotel, Washington, DC.

*Contact Person:* Dr. Bob Weller, Scientific Review Administrator, 6701 Rockledge Drive, Room 5204, Bethesda, MD 20892, (301) 435-1261.

*Name of SEP:* Clinical Sciences.

*Date:* June 30, 1995.

*Time:* 8:30 a.m.

*Place:* Holiday Inn, Chevy Chase, MD.

*Contact Person:* Dr. Daniel McDonald, Scientific Review Administrator, 6701 Rockledge Drive, Room 4214, Bethesda, MD 20892, (301) 435-1215.

*Name of SEP:* Clinical Sciences.

*Date:* July 12, 1995.

*Time:* 1:00 p.m.

*Place:* NIH, Rockledge II, Room 4218, Telephone Conference.

*Contact Person:* Dr. Shirley Hilden, Scientific Review Admin., 6701 Rockledge Drive, Room 4218, Bethesda, MD 20892, (301) 435-1197.

*Name of SEP:* Biological and Physiological Sciences.

*Date:* July 14, 1995.

*Time:* 1:30 p.m.

*Place:* NIH, Rockledge II, Room 5122, Telephone Conference.

*Contact Person:* Dr. Michael Lang, Scientific Review Administrator, 6701 Rockledge Drive, Room 5122, Bethesda, MD 20892, (301) 435-1015.